{
  "id": 19389843,
  "title": "Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention",
  "url": "https://urgent.news/2026/11/10/next-gen-anticoagulant-lands-fda-nod-for-secondary-stroke-prevention",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T19:18:57.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/cardiology/strokes/123815"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday. Asundexian, an oral, direct, small-molecule inhibitor of FXIa, is indicated for...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}